Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood Vessels

Rhea-AI Summary

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced the filing of a patent for a unique cell designed to train the immune system to target cancerous blood vessels while preserving healthy vessels. This innovation builds on prior findings showing StemVacs' ability to suppress new blood vessel formation. The company's new product, StemVacs-V™, is a chimeric cell derived from engineered iPSC cells, demonstrating selective killing of malignant blood vessels, which could offer significant therapeutic potential.

Positive

• Filing of a patent for a novel cell that targets cancer blood vessels.
• Potential therapeutic implications based on findings from animal studies.
• StemVacs-V™ integrates iPSC technology with immune stimulation.

Negative

• None.

ELK CITY, Idaho, March 23, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent with new data on a unique cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels.  These data are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. 

"Killing malignant blood vessels is the basis for Avastin, an antibody-based drug which created 7 billion in revenue last year.¹  Another company, Batu Biologics, previously demonstrated vaccination against cancer blood vessels is safe and was cleared by the FDA for clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company.  "The approach developed by our Company is completely unique because it merges the potent antigen presenting capabilities of StemVacs-V together with the reproducibility and consistency of iPSC generated tumor-like endothelial cells."

StemVacs-V™ is comprised of "cancer resistant" dendritic cells which are developed from an engineered iPSC cell line.  The novel chimeric cell product is generated by fusing StemVacs-V with iPSC derived endothelial cells which are cultured in a manner to make them replicate cancer stem cells.  Proof of selective killing of cancer blood vessels was obtained by demonstration of immune response to proteins found only on cancer blood vessels.

"Numerous companies such as Fate Therapeutics, NantKwest, and Century Therapeutics have all achieved significant valuations through pioneering novel uses of iPSC derived immune cells," said Famela Ramos, Vice President of Business Development. "To our knowledge we are the first company to use iPSC derived cells to stimulate naturally occurring immunity to kill what some call the 'Achilles Heel' of cancer."

"Generation of a new cell that didn't previously exist is a significant milestone for our Company.  We believe the current animal studies in lung cancer can be extrapolated to other cancers, since no cancer can grow more than 2 millimeters without creating new blood vessels," said Timothy Dixon, President and CEO of the Company and co-inventor of the patent.  "By selectively killing cancer blood vessels the problem of mutations is solved since cancer blood vessels are not generated from tumor tissue and they do not mutate.  Furthermore, since blood vessels are in direct contact with the blood and immune cells that travel through the blood, it is substantially easier for the immune system to kill malignant vessels as opposed to tumors."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

¹ https://www.fiercepharma.com/special-report/top-20-drugs-by-global-sales-2019-avastin 

ir@tsoimail.com

 

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-creates-hybrid-cell-designed-to-educate-immune-system-to-choke-cancer-blood-vessels-301253715.html

SOURCE Therapeutic Solutions International

FAQ

What is the significance of the patent filed by Therapeutic Solutions International (TSOI)?

The patent signifies a major development in creating a cell that can train the immune system to attack cancer blood vessels while sparing healthy ones.

How does StemVacs-V™ differ from existing cancer treatments?

StemVacs-V™ uniquely combines engineered iPSC cells with the immune system’s capabilities to selectively target and kill cancerous blood vessels.

What are the potential market implications for Therapeutic Solutions International (TSOI) with this new cell?

If successful, this innovation could position TSOI competitively in the cancer treatment market, similar to successful products like Avastin.

What prior findings support the development of this new cell by TSOI?

Previous findings indicated that StemVacs can suppress new blood vessel production, providing a foundation for the new patent.

What is the expected timeline for clinical trials for the new cell developed by TSOI?

The press release does not specify a timeline for clinical trials regarding the new cell.